Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook

Myriad Genetics (MYGN) PT Raised to $37 at Needham & Company

February 6, 2019 8:05 AM EST

Needham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while maintaining a Strong Buy rating.

Unger commented, "We are updating our financial model for MYGN following last night's release of FY2Q19 results. Our... More